Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
R
R
Frothingham
D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D015658:HIV Infections / Q000188:drug therapy / Q000191:economics* / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D019469:Indinavir / Q000191:economics; D019259:Lamivudine / Q000191:economics; D016273:Occupational Exposure / Q000009:adverse effects*; D014481:United States; D015215:Zidovudine / Q000191:economics
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir